2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 96-105

  Ma, Li ^a   Li, Guangxin ^b   Zhu, Huaqiang ^c   Dong, Xuesong ^a   Zhao, Dali ^a   Jiang, Xian ^a   Li, Jie ^b   Qiao, Haiquan ^a   Ni, Shaobin ^a   Sun, Xueying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

2 Methoxyestradiol; Hepatocellular carcinoma; Hypoxia inducible factors; Sorafenib

Indexed keywords

2 METHOXYESTRADIOL; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; MESSENGER RNA; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN; 2-METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CARBANILAMIDE DERIVATIVE; CCND1 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; ESTRADIOL; HIF1A PROTEIN, HUMAN; ISOENZYME; LACTATE DEHYDROGENASE 5; NICOTINAMIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL VIABILITY; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE; GENE EXPRESSION; HIF 1ALPHA GENE; HIF 2ALPHA GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; LDHA GENE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; VEGF GENE; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME; VASCULARIZATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTRADIOL; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907974476     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.011     Document Type: Article

References (45)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90. 10.3322/caac.20107.
2. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. 10.1002/hep.24199.
3. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med 2008, 359:378-390. 10.1056/NEJMoa0708857.
4. Kelley R.K., Nimeiri H.S., Munster P.N., Vergo M.T., Huang Y., Li C.M., et al. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann. Oncol 2013, 24:1900-1907. 10.1093/annonc/mdt109.
5. Lee S.J., Lee J., Park S.H., Park J.O., Park Y.S., Kang W.K., et al. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest. New Drugs 2012, 30:1540-1547. 10.1007/s10637-011-9706-5.
6. Bottsford-Miller J.N., Coleman R.L., Sood A.K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol 2012, 30:4026-4034. 10.1200/JCO.2012.41.9242.
7. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008, 15:678-685. 10.1038/cdd.2008.21.
8. Murakami M., Zhao S., Zhao Y., Chowdhury N.F., Yu W., Nishijima K., et al. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int. J. Oncol 2012, 41:1593-1600. 10.3892/ijo.2012.1624.
9. Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22. 10.1038/nrc3183.
10. Loboda A., Jozkowicz A., Dulak J. HIF-1 and HIF-2 transcription factors - similar but not identical. Mol. Cells 2010, 29:435-442. 10.1007/s10059-010-0067-2.
11. Lin Q., Cong X., Yun Z. Differential hypoxic regulation of hypoxia-inducible factors 1 α and 2 α. Mol. Cancer Res 2011, 9:757-765. 10.1158/1541-7786.MCR-11-0053.
12. Menrad H., Werno C., Schmid T., Copanaki E., Deller T., Dehne N., et al. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology 2010, 51:2183-2192. 10.1002/hep.23597.
13. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10:413-423. 10.1016/j.ccr.2006.08.026.
14. Uchida T., Rossignol F., Matthay M.A., Mounier R., Couette S., Clottes E., et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J. Biol. Chem 2004, 279:14871-14878. 10.1074/jbc.M400461200.
15. Koh M.Y., Lemos R., Liu X., Powis G. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 2011, 71:4015-4027. 10.1158/0008-5472.CAN-10-4142.
16. Seton-Rogers S. Hypoxia: HIF switch. Nat. Rev. Cancer 2011, 11:391. 10.1038/nrc307.
17. Liu L.P., Ho R.L., Chen G.G., Lai P.B. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer Res 2012, 18:5662-5671. 10.1158/1078-0432.CCR-12-0552.
18. Zhao D., Zhai B., He C., Tan G., Jiang X., Pan S., et al. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell. Signal 2014, 26:1030-1039. 10.1016/j.cellsig.2014.01.026.
19. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375. 10.1016/S1535-6108(03)00077-1.
20. El Naga R.N., El-Demerdash E., Youssef S.S., Abdel-Naim A.B., El-Merzabani M. Cytotoxic effects of 2-methoxyestradiol in the hepatocellular carcinoma cell line HepG2. Pharmacology 2009, 84:9-16. 10.1159/000221062.
21. Kar S., Wang M., Carr B.I. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother. Pharmacol 2008, 62:831-840. 10.1007/s00280-007-0670-x.
22. He C., Sun X.P., Qiao H., Jiang X., Wang D., Jin X., et al. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci 2012, 103:528-534. 10.1111/j.1349-7006.2011.02177.x.
23. Wang J., Ma Y., Jiang H., Zhu H., Liu L., Sun B., et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. J. Hepatol 2011, 55:359-368. 10.1016/j.jhep.2010.10.043.
24. Zhai B., Hu F., Jiang X., Xu J., Zhao D., Liu B., et al. Inhibition of Akt reverses the acquired resistance to sorafenib by inducing autophagic cell death in hepatocellular carcinoma. Mol. Cancer Ther 2014, 13:1589-1598. 10.1158/1535-7163.MCT-13-1043.
25. Xiu P., Dong X., Dong X., Xu Z., Zhu H., Liu F., et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 2013, 104:375-382. 10.1111/cas.12088.
26. Mai Z., Blackburn G.L., Zhou J.R. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis 2007, 28:1217-1223. 10.1093/carcin/bgm004.
27. Villanueva A., Llovet J.M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res 2012, 18:1824-1826. 10.1158/1078-0432.CCR-12-0151.
28. Santoro A., Rimassa L., Borbath I., Daniele B., Salvagni S., Van Laethem J.L., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013, 14:55-63. 10.1016/S1470-2045(12)70490-4.
29. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410. 10.1038/nrc3064.
30. Xia Y., Choi H.K., Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem 2012, 49:24-40. 10.1016/j.ejmech.2012.01.033.
31. Verenich S., Gerk P.M. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol. Pharm 2010, 7:2030-2039. 10.1021/mp100190f.
32. Sun X., Vale M., Jiang X., Gupta R., Krissansen G.W. Antisense HIF-1 prevents acquired tumour resistance to the anti-angiogenic drug angiostatin. Cancer Gene Ther 2010, 17:532-540. 10.1038/cgt.2010.7.
33. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468. 10.1126/science.1059817.
34. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166. 10.1038/nrc2602.
35. Parekh P., Rao K.V. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive Liver carcinogenesis. Cell Biol. Int 2007, 31:35-43.
36. Shi M., Cui J., Du J., Wei D., Jia Z., Zhang J., et al. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin. Cancer Res 2014, 20:4370-4380.
37. Girgis H., Masui O., White N.M., Scorilas A., Rotondo F., Seivwright A., et al. Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol. Cancer 2014, 13:101. 10.1186/1476-4598-13-101.
38. Ehteda A., Galettis P., Pillai K., Morris D.L. Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. BMC Cancer 2013, 13:86. 10.1186/1471-2407-13-86.
39. Kang S.H., Cho H.T., Devi S., Zhang Z., Escuin D., Liang Z., et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006, 66:11991-11997. 10.1158/0008-5472.CAN-06-1320.
40. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res 2004, 10:8665-8673. 10.1158/1078-0432.CCR-04-1393.
41. Ganapathy M., Ghosh R., Jianping X., Zhang X., Bedolla R., Schoolfield J., et al. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin. Cancer Res 2009, 15:1601-1611. 10.1158/1078-0432.CCR-08-1389.
42. Rajkumar S.V., Richardson P.G., Lacy M.Q., Dispenzieri A., Greipp P.R., Witzig T.E., et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res 2007, 13:6162-6167. 10.1158/1078-0432.CCR-07-0807.
43. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther 2006, 5:22-27. 10.4161/cbt.5.1.2349.
44. James J., Murry D.J., Treston A.M., Storniolo A.M., Sledge G.W., Sidor C., et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-Methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs 2006, 25:41-48. 10.1007/s10637-006-9008-5.
45. Lee I., Seong Choe Y., Jung K.H., Lee K.H., Young Choi J., Choi Y., et al. 2-[methyl-(11)C] methoxyestradiol: synthesis, evaluation and pharmacokinetics for in vivo studies on angiogenesis. Nucl. Med. Biol 2007, 34:625-631. 10.1016/j.nucmedbio.2007.06.004.